POTOMAC, MD / ACCESS Newswire / January 6, 2026 / IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE American:IGC), a clinical-stage pharmaceutical company leveraging Artificial Intelligence (AI) to develop innovative treatments for Alzheimer's disease, today announced that its Board of Directors has approved a change in the Company's fiscal year end from March 31 to December 31, effective December 31, 2025. "This is a straightforward but important step in strengthening how we engage with U.S. i ...

公司活动安排 - 公司将于2025年11月17日东部时间上午11点举行电话会议和网络直播 [1] 公司业务与报告期 - 公司为临床阶段生物技术公司 专注于利用人工智能开发阿尔茨海默病创新疗法 [1] - 电话会议将回顾公司截至2025年9月30日的第二季度及年中运营进展 [1]